Tenders Are Invited For Various Medicinal Products – Supply Of The Medicinal Product Sorafenibum For A Non-Commercial Clinical Trial (Dragonfly)

Various Medicinal Products – Supply Of The Medicinal Product Sorafenibum For A Non-Commercial Clinical Trial (Dragonfly). The Subject Of The Order Is The Supply Of The Medicinal Product Sorafenibum For A Non-Commercial Clinical Trial (Dragonfly). A Detailed Description And Method Of Order Execution Are Included In The Assortment And Price Table Constituting Annex No. 2 To The Swz, And The Contract Template Constituting Annex No. 4 To The Swz. The Proceedings Are Carried Out As Part Of The Project Called: Evaluation Of The Safety And Efficacy Of Mifamurtide Versus Standard Treatment With Sorafenib In Patients With High-Risk Osteosarcoma. / Evaluation Of The Safety And Effectiveness Of Mifamurtide Compared To Standard Treatment Containing Sorafenib In Patients With High-Risk Osteosarcoma (Dragonfly). The Ordering Party In Accordance With The Act Of March 9, 2023 On Clinical Trials Of Medicinal Products For Human Use (Hereinafter Also Referred To As The Act) Acts As The Sponsor Of Non-Commercial Clinical Trials Included In The Above-Mentioned Project, Implemented Under Agreement No. 2024/Abm/02/00010-00 For Co-Financing Of A Non-Commercial Clinical Trial Project Of August 29, 2025, Concluded With The Medical Research Agency (Abm). The Ordering Party Does Not Allow The Submission Of Partial Offers. The Subject Of The Order Is Only One Substance And Therefore It Is Not Possible To Divide The Order Into Parts. Order Declares That, As The Data Administrator And Taking Into Account The Provisions Of The Act Of May 10, 2018 On The Protection Of Personal Data (Hereinafter Referred To As Gdpr), It Has Implemented Security Measures Adequate To The Risks It Has Identified And Guaranteeing Proper Protection Of Personal Data Transferred As Part Of The Proceedings. Detailed Information Clause From Art. 13 Gdpr Is Included In The Swz.